SCHEMBL417011

SCHEMBL417011

CCOC(=O)c1cc(-c2cc(F)cc(Cl)c2)co1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 1/20 0.42
MAOB P27338 2/20 0.39
CHRNA4 P43681 2/20 0.38
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CETP P11597 1/20 0.36
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.35
CNR2 P34972 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
BAZ2B Q9UIF8 1/20 0.35
BAZ2A Q9UIF9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418294 0.80 TRPM8 (0.50) MAOBMAPTL3MBTL1MAPK1
SCHEMBL17530795 0.80 XPO1 (0.41) XPO1MAPTL3MBTL1CNR2TARBP2
SCHEMBL419322 0.79 XPO1 (0.43) XPO1MAOBALDH1A1POLBMAPT
SCHEMBL31341276 0.76 XPO1 (0.45) XPO1MAOBALDH1A1POLBMAPT
SCHEMBL417954 0.71 ALOX5 (0.40) XPO1MAOBALDH1A1POLBMAPT
SCHEMBL29591835 0.70 LMNA (0.49) MAOBALDH1A1MAPTHTTHDAC4
SCHEMBL10102795 0.70 CA12 (0.44) MAOBL3MBTL1HDAC4HDAC6MAPK1
Hydrochloric Acid SCHEMBL29593023 0.69 LMNA (0.47) MAOBALDH1A1MAPTHTTHDAC4
Hydrochloric Acid SCHEMBL26983112 0.69 LMNA (0.47) MAOBALDH1A1MAPTHTTHDAC4
SCHEMBL23794581 0.69 XPO1 (0.51) XPO1ALDH1A1POLBMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT XPO1 3828/4885MAOB 272/4885CHRNA4 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.